Capricor Therapeutics to Participate in Notable Investor Conferences
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a pioneering biotechnology company known for its innovative cell and exosome-based therapies targeting rare diseases, has exciting plans to participate in a series of investor conferences. These events are crucial for highlighting the company’s advancements, particularly in the treatment of Duchenne muscular dystrophy (DMD).
Upcoming Events Where Capricor Will Present
The following key events are scheduled for Capricor management to engage with investors and the broader healthcare community:
Oppenheimer 35th Annual Healthcare Life Sciences Conference
On the 12th of February, 2025, from 12:00 to 12:30 p.m. ET, Capricor will participate in this virtual conference. This event serves as a platform for Capricor to discuss their lead program, deramiocel, and share key updates on their scientific developments. Attendees can access the virtual presentation to learn more about their progress.
Barclays 27th Annual Global Healthcare Conference
Capricor is also set to take part in this conference, taking place from March 11 to March 13, 2025. This event will garner attention from investors eager to learn about the latest innovations in biotechnology and specifically Capricor's advancements in treating DMD.
37th Annual ROTH Conference
This conference, scheduled for March 16 to 18, 2025, in Dana Point, CA, will further provide Capricor's management with the opportunity to outline their strategic vision and elaborate on their product advancements. Engaging with investors will be a priority as these discussions may shed light on the company’s growth trajectory.
Management Insights and Company Mission
During these conferences, Capricor's management is eager to present updates on deramiocel, an innovative therapy designed for individuals suffering from DMD. This product candidate has shown promise in preclinical and clinical studies, demonstrating unique immunomodulatory, antifibrotic, and regenerative properties.
Capricor's commitment to advancing science is showcased through their proprietary StealthX™ technology, which aims to facilitate targeted therapeutic delivery. This positions Capricor at the forefront of biotechnology aimed at redefining treatment protocols across various rare diseases.
Capricor's Vision for the Future
Capricor Therapeutics remains dedicated to revolutionizing the treatment landscape for rare diseases. Through their innovative therapeutic solutions, the company is not only pursuing regulatory approvals but also engaging with the community for collaboration and growth. They stand at a pivotal moment, ready to make significant strides in medical breakthroughs.
Frequently Asked Questions
What is the focus of Capricor Therapeutics' presentations at the conferences?
Capricor will present updates on their lead product candidate, deramiocel, aimed at treating Duchenne muscular dystrophy and general scientific advancements.
When and where will Capricor present at the Oppenheimer conference?
Capricor will present on February 12, 2025, from 12:00 to 12:30 p.m. ET during the Oppenheimer 35th Annual Healthcare Life Sciences Conference, virtually.
What other conferences is Capricor attending?
Capricor will also be participating in the Barclays 27th Annual Global Healthcare Conference and the 37th Annual ROTH Conference in March 2025.
What are the key products being discussed by Capricor?
The focus will primarily be on deramiocel (CAP-1002) and its development process for treating Duchenne muscular dystrophy (DMD).
How is Capricor advancing its technology?
Capricor employs its proprietary StealthX™ platform to enhance therapeutic delivery, aiming for innovative treatments in various disease areas.
